FindMyKOL
Clinical trialNCT05553236RecruitingInterventional

Pragmatic Use of Next-generation Sequencing for Management of Drug-resistant Tuberculosis

SponsorUniversity of California, San FranciscoEnrollment2,500Cost-Benefit AnalysisDrug-resistant TuberculosisHIV Coinfection
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

TS ELiOT is a stepped-wedge, cluster randomized trial assessing the effect of a next-generation sequencing-based strategy on rifampin-resistant tuberculosis management and patient outcomes.

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

South Africa
  • South African National Health Laboratory Service

    Cape Town, South Africa

    Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study. It may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
1 Aug 2024
Primary completion
31 Jan 2027
Completion
31 Jan 2027
Last update posted
26 Jan 2026
Registered enrollment
2,500
Registry id
NCT05553236

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 11 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.